BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, today announced that new translational data for NiCord®, an investigational cell therapy in Phase 3 clinical development for allogeneic stem cell, or bone marrow, transplant, will be presented at the American Society of Hematology (ASH) 2018 Annual Meeting, which is being held December 1-4 in San Diego, CA.
Details about the poster presentation are as follows:
Presentation
Time: Saturday, December 1, 2014, 6:15 p.m. – 8:15 p.m. PT
Title:
Rapid and Robust CD4+ and CD8+ T-, NK-, B- and Monocyte Cell
Reconstitution after Nicotinamide-Expanded Cord Blood Transplantation
Abstract
Number: 2123
Lead Author: Jaap Jan Boelens, M.D., Ph.D.,
Pediatric Blood and Marrow Transplantation Program, University Medical
Center Utrecht, Utrecht, Netherlands
Location: San Diego
Convention Center, Hall GH
About NiCord
NiCord, the company’s lead clinical program, is
under development as a universal bone marrow transplant solution for
patients with high-risk hematologic malignancies. NiCord has
demonstrated improved efficacy over standard cord blood, including fewer
bacterial and fungal infections and a reduction in duration of hospital
stays. NiCord has been granted breakthrough status by the U.S. Food and
Drug Administration, making it the first bone marrow transplant
alternative to receive this designation. It has also received U.S. and
EU orphan drug designation. A Phase 3 study evaluating NiCord in
patients with leukemia and lymphoma is ongoing in the United States,
Europe and Asia (NCT02730299). For more information on NiCord clinical
trials, please visit www.clinicaltrials.gov.
About Gamida Cell
Gamida Cell is a clinical stage
biopharmaceutical company leveraging its proprietary technology to
develop cell therapies that are designed to cure cancer and rare,
serious hematologic diseases. The company is leveraging its
nicotinamide-, or NAM-, based cell expansion technology to develop a
pipeline of products designed to address the limitations of cell
therapies.
